Abstract
ACP Journal Club19 March 2013Aliskiren increased adverse events in patients with diabetes and kidney disease who were receiving ACE inhibitors or ARBsPeter W. de Leeuw, MDPeter W. de Leeuw, MDMaastricht University Medical Centre and, Cardiovascular Research Institute Maastricht (CARIM), Maastricht, The Netherlands (P.W.D.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-158-6-201303190-02007 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Source CitationParving HH, Brenner BM, McMurray JJ, et al; ALTITUDE Investigators. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012;367:2204-13. https://pubmed.ncbi.nlm.nih.gov/23121378Clinical Impact RatingsCardiology: Endocrinology: Nephrology: References1 Pogue J, Devereaux PJ, Thabane L, Yusuf S. Designing and analyzing clinical trials with composite outcomes: consideration of possible treatment differences between the individual outcomes. PLoS One. 2012;7:e34785. [PMID: 22529934] Google Scholar2 ONTARGET Investigators, Yusuf S, Teo KK, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547-59. [PMID: 18378520] Google Scholar3 Harel Z, Gilbert C, Wald R, et al. The effect of combination treatment with aliskiren and blockers of the renin-angiotensin system on hyperkalaemia and acute kidney injury: systematic review and meta-analysis. BMJ. 2012;344:e42. [PMID: 22232539] Google Scholar4 Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349:1893-906. [PMID: 14610160] Google Scholar Author, Article, and Disclosure InformationAffiliations: Maastricht University Medical Centre and, Cardiovascular Research Institute Maastricht (CARIM), Maastricht, The Netherlands (P.W.D.)This article was published at Annals.org on 5 March 2013. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByKidney Disease End Points in a Pooled Analysis of Individual Patient–Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 DiabetesAliskiren, the first direct renin inhibitor: assessing a role in pediatric hypertension and kidney diseasesRenoprotective effect of renal liver-type fatty acid binding protein and angiotensin II type 1a receptor loss in renal injury caused by RAS activationScreening, Early Diagnosis, Genetic Markers, and Predictors of Diabetic Nephropathy 19 March 2013Volume 158, Issue 6Page: JC7KeywordsACE inhibitorsAdverse eventsCardiovascular therapyChronic kidney diseaseHeartHeart failureHypotensionLongitudinal studiesRenal diseasesType 2 diabetes ePublished: 19 March 2013 Issue Published: 19 March 2013 CopyrightCopyright © 2013 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
